Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2005-11-08
2005-11-08
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S178100, C424S182100, C424S183100, C424S195110, C424S197110, C530S391700
Reexamination Certificate
active
06962694
ABSTRACT:
A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein. A targeted immune modulator, characterized in that it is a conjugate between a targeting moiety (T″′) and a modified immune modulator (IM″′). The conjugate complies with a formula analogous to formula (1) except for the imperative presence of the modified immune modulator. A superantigen moiety may be present. A DNA molecule encoding a superantigen and an immune modulator.
REFERENCES:
patent: 5705151 (1998-01-01), Dow et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 9601650 (1996-01-01), None
patent: 9736932 (1997-10-01), None
Belfrage et al, Immunology, 90, 183-188, 1997.
Lando et al, Journal of Immunology, 157, 2857-2863, 1996.
Abrahmsen Lars
Dohlsten Mikael
Forsberg Goran
Kalland Terje
Lando Peter
Active Biotech AG
Fox David L.
Fulbright & Jaworski LLP
Saunders David
LandOfFree
Cytolysis of target cells by superantigen conjugates... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytolysis of target cells by superantigen conjugates..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytolysis of target cells by superantigen conjugates... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479203